News
Evolva statement to SER communication
Condor Technologies nimmt den Handel an der Börse Euronext in Paris wieder auf
Wir freuen uns, Ihnen die Wiederaufnahme des Handels von Condor Technologies (MLMFI.PA) am 23. August an der Euronext Access Exchange in Paris mitteilen zu dürfen.
Die Wiederaufnahme des Handels
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA)
Condor Technologies to Reopen Trading on the Euronext Exchange in Paris
We are pleased to announce the reopening of the trading sessions on August 23rd for Condor Technologies (MLMFI.PA) on the Euronext Access Exchange in Paris.
The resumption of the trading
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
QIAGEN veröffentlicht Nachhaltigkeitsbericht 2021
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat große Fortschritte im ESG-Bereich erzielt (Umwelt, Soziales, Governance), die das Unternehmen im heute veröffentlichten Nachhaltigkeitsbericht
QIAGEN Issues 2021 Sustainability Report
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2021 Sustainability Report, outlining significant achievements in the areas of Environment, Social and Governance (ESG) as part
Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a
QuidelOrtho Announces $300 Million Share Repurchase Authorization
QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
DGAP-News: M1 Kliniken AG announces financials for H1-2022: positive business development despite cooling of general consumer climate
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Agilent Reports Third-Quarter Fiscal Year 2022 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the third quarter ended July 31, 2022, an increase of 8% compared to the third quarter of 2021 and up 13% on a core(1
DGAP-News: Abivax announces a change in its governance
DGAP-News: Burcon Reports Fiscal 2023 First Quarter Results
Premier, Inc. Reports Fiscal-Year 2022 Fourth-Quarter and Full-Year Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2022 fourth quarter and full year ended June 30, 2022